Soleno Therapeutics

Neurocrine Biosciences0K6R · BiotechSan Diego, United States

70% matchPublicAI 6/100 ▼Green 3/100 ▼

Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for a range of neurological, endocrine, and psychiatric conditions. Its established portfolio offers solutions for conditions such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids. Foremost among its commercialized offerings is INGREZZA, a VMAT2 inhibitor specifically indicated for treating tardive dyskinesia. Other key commercialized therapies include ONGENTYS, a catechol-O-methyltransferase inhibitor functioning as an adjunctive treatment alongside levodopa/DOPA decarboxylase inhibitors for individuals with Parkinson's disease. Additionally, ORILISSA is available for women experiencing moderate to severe endometriosis pain, and ORIAHNN provides an oral, non-surgical option for pre-menopausal women managing heavy menstrual bleeding linked to uterine fibroids. Beyond its marketed drugs, Neurocrine Biosciences maintains a robust pipeline of investigational compounds. This includes NBI-921352, which is being developed to address both pediatric patients and adults with focal epilepsy, and NBI-827104, aimed at rare pediatric epilepsy and essential tremor. Further additions to the clinical development portfolio encompass NBI-1065845 for major depressive disorder (MDD), NBI-1065846 specifically targeting anhedonia within MDD, and NBI-118568, an agent under investigation for schizophrenia. To further its research and development efforts, the company has established strategic alliances and licensing agreements with a notable roster of partners, including Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL – Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Established in 1992, Neurocrine Biosciences, Inc. maintains its headquarters in San Diego, California.

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.

Awakn Life Sciences Inc.BiotechnologyCanada

69% matchPrivate

Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.

Neurogastrx, Inc.BiotechnologyUnited States

67% matchPrivate

Neurogastrx, Inc. is a pharmaceutical manufacturing company founded in 2012. Its main headquarters is located at 500 Unicorn Park Drive in Woburn, Massachusetts, where it is passionate about developing therapies to advance treatment.

AribioBiotechnologySouth Korea

67% match

AriBio is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Seongnam, South Korea, with additional offices in the United States. The company focuses on developing novel therapeutics for neurodegenerative diseases.

Protagenic Therapeutics, Inc.newPTIX · BiotechNew York, United States

67% matchPublic

Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.